Key result
The combination of clopidogrel and aspirin significantly reduced maximum thrombus peak compared to baseline (263 vs 800 pixels/μm2, p<0.0001) and induced marked dethrombosis in all 20 healthy volunteers.
Why the study?
Does treatment with antiplatelet agents and their combinations affect the kinetics of thrombus growth and stability in a real-time perfusion chamber assay?
Does treatment with antiplatelet agents and their combinations affect the kinetics of thrombus growth and stability in a real-time perfusion chamber assay?
Absolute Event Rate: 263% vs 800%
p-value: p=<0.0001
A novel perfusion chamber assay allows for real-time pharmacodynamic monitoring of arterial thrombosis and demonstrates that dual antiplatelet therapy consistently destabilizes thrombi even in individuals non-responsive to monotherapy.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for perfusion chamber monitoring of antiplatelet effects; validation in patients needed before clinical use.
Stephens et al. (2012) studied Healthy volunteers (n=20). Clopidogrel and Aspirin vs. Baseline was evaluated on Maximum peak of thrombus formation (pixels/μm2) (p=<0.0001). The combination of clopidogrel and aspirin significantly reduced maximum thrombus peak compared to baseline (263 vs 800 pixels/μm2, p<0.0001) and induced marked dethrombosis in all 20 healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: